Compare PAR & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAR | NVCR |
|---|---|---|
| Founded | 1968 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Medical/Dental Instruments |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | N/A | 2015 |
| Metric | PAR | NVCR |
|---|---|---|
| Price | $37.41 | $13.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $64.00 | $28.42 |
| AVG Volume (30 Days) | 552.8K | ★ 1.9M |
| Earning Date | 11-06-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $440,451,000.00 | ★ $642,269,000.00 |
| Revenue This Year | $30.40 | $9.75 |
| Revenue Next Year | $12.01 | $5.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 39.88 | 11.17 |
| 52 Week Low | $31.65 | $10.70 |
| 52 Week High | $77.66 | $32.06 |
| Indicator | PAR | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 57.31 | 60.58 |
| Support Level | $35.17 | $12.30 |
| Resistance Level | $38.15 | $13.94 |
| Average True Range (ATR) | 1.50 | 0.61 |
| MACD | 0.31 | 0.09 |
| Stochastic Oscillator | 79.08 | 86.51 |
PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). The company's product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.